OTCMKTS:MKGAF

MERCK Kommanditgesellschaft auf Aktien News Headlines

$174.00
+8.20 (+4.95 %)
(As of 05/7/2021 08:28 PM ET)
Add
Compare
Today's Range
$174.00
▼
$174.38
50-Day Range
$160.60
▼
$177.75
52-Week Range
$107.50
▼
$182.85
Volume100 shs
Average Volume461 shs
Market Capitalization$22.49 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.7

Headlines

MERCK Kommanditgesellschaft auf Aktien (OTCMKTS MKGAF) News Headlines Today

SourceHeadline
MERCK Kommanditgesellschaft auf Aktien (OTCMKTS:MKGAF) Short Interest Down 31.6% in AprilMERCK Kommanditgesellschaft auf Aktien (OTCMKTS:MKGAF) Short Interest Down 31.6% in April
americanbankingnews.com - May 1 at 4:54 PM
MERCK Kommanditgesellschaft auf Aktien (OTCMKTS:MKGAF) Short Interest Up 27.8% in MarchMERCK Kommanditgesellschaft auf Aktien (OTCMKTS:MKGAF) Short Interest Up 27.8% in March
americanbankingnews.com - April 19 at 11:20 AM
Germanys Merck in fresh investment to make bioreactor gear in FranceGermany's Merck in fresh investment to make bioreactor gear in France
finance.yahoo.com - March 17 at 2:59 PM
Gileads remdesivir to be tested with Merck KGaAs interferon vs. COVID by NIHGilead's remdesivir to be tested with Merck KGaA's interferon vs. COVID by NIH
feeds.marketwatch.com - August 7 at 11:14 AM
ERBITUX® Approved for First-line Use in China in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)ERBITUX® Approved for First-line Use in China in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)
finance.yahoo.com - March 2 at 3:33 AM
Does MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) CEO Pay Matter?Does MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) CEO Pay Matter?
finance.yahoo.com - January 22 at 3:56 AM
Merck KGaA to reconsider selling allergy business - BloombergMerck KGaA to reconsider selling allergy business - Bloomberg
seekingalpha.com - January 9 at 3:34 PM
Versum Materials Announces China Antitrust Clearance of Merger with Merck KGaA, Darmstadt, Germany; Announces Expected Closing DateVersum Materials Announces China Antitrust Clearance of Merger with Merck KGaA, Darmstadt, Germany; Announces Expected Closing Date
www.businesswire.com - October 1 at 10:52 AM
Merck KGaAs Q2 profit bolstered by drug milestone paymentsMerck KGaA's Q2 profit bolstered by drug milestone payments
feeds.reuters.com - August 8 at 3:51 AM
UPDATE 1-Merck KGaAs profit bolstered by lab supplies, drug milestone paymentsUPDATE 1-Merck KGaA's profit bolstered by lab supplies, drug milestone payments
feeds.reuters.com - August 8 at 3:51 AM
Merck KGaA sees currencies supporting 2019 outlookMerck KGaA sees currencies supporting 2019 outlook
feeds.reuters.com - May 14 at 2:43 AM
Merck KGaA Signs Versum Buyout Deal; Entegris Receives Termination PaymentMerck KGaA Signs Versum Buyout Deal; Entegris Receives Termination Payment
feeds.benzinga.com - April 12 at 12:22 PM
Merck KGaA agrees $6.5 bln takeover of VersumMerck KGaA agrees $6.5 bln takeover of Versum
feeds.reuters.com - April 12 at 9:37 AM
UPDATE 2-Merck KGaA wins Versums support for sweetened $6.5 bln offerUPDATE 2-Merck KGaA wins Versum's support for sweetened $6.5 bln offer
feeds.reuters.com - April 8 at 11:07 AM
FDA OKs Merck KGaAs MS med MavencladFDA OKs Merck KGaA's MS med Mavenclad
seekingalpha.com - March 30 at 10:30 PM
UPDATE 3-Versum opens books, begins to warm to rival suitor Merck KGaAUPDATE 3-Versum opens books, begins to warm to rival suitor Merck KGaA
feeds.reuters.com - March 29 at 3:40 PM
UPDATE 3-Merck KGaA goes hostile in $5.9 bln Versum takeover battleUPDATE 3-Merck KGaA goes hostile in $5.9 bln Versum takeover battle
feeds.reuters.com - March 26 at 1:36 PM
Merck KGaA calls on Versum investors to vote down Entegris mergerMerck KGaA calls on Versum investors to vote down Entegris merger
feeds.reuters.com - March 12 at 12:46 PM
UPDATE 1-Merck KGaA urges Versum shareholders to support takeover bidUPDATE 1-Merck KGaA urges Versum shareholders to support takeover bid
feeds.reuters.com - March 5 at 8:58 AM
UPDATE 1-Versum Materials rejects Merck KGaAs unsolicited offerUPDATE 1-Versum Materials rejects Merck KGaA's unsolicited offer
feeds.reuters.com - March 1 at 2:36 PM
Germanys Merck makes $5.9 billion cash counterbid for VersumGermany's Merck makes $5.9 billion cash counterbid for Versum
feeds.reuters.com - February 27 at 8:42 AM
GlaxoSmithKline plc (GSK) Q4 2018 Earnings Conference Call TranscriptGlaxoSmithKline plc (GSK) Q4 2018 Earnings Conference Call Transcript
finance.yahoo.com - February 6 at 3:26 PM
GlaxoSmithKline and Merck KGaA strike immunotherapy deal worth up to $4 billionGlaxoSmithKline and Merck KGaA strike immunotherapy deal worth up to $4 billion
www.marketwatch.com - February 5 at 9:33 AM
Pfizer's (PFE) New Lung Cancer Drug Vizimpro Gets CHMP NodPfizer's (PFE) New Lung Cancer Drug Vizimpro Gets CHMP Nod
finance.yahoo.com - February 4 at 3:25 PM
Merck KGaA Gives Vertex Rights to Two Gene-Editing CompoundsMerck KGaA Gives Vertex Rights to Two Gene-Editing Compounds
finance.yahoo.com - January 25 at 3:25 PM
Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian CancerMerck KGaA, Darmstadt, Germany, and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian Cancer
finance.yahoo.com - December 21 at 3:18 PM
Merck KGaA-Pfizer to end late-stage ovarian cancer treatment studyMerck KGaA-Pfizer to end late-stage ovarian cancer treatment study
finance.yahoo.com - December 21 at 3:18 PM
Merck KGaA-Pfizer to terminate late-stage ovarian cancer treatment studyMerck KGaA-Pfizer to terminate late-stage ovarian cancer treatment study
feeds.reuters.com - December 21 at 3:08 PM
CORRECTED-UPDATE 1-Merck KGaA-Pfizer to end late-stage ovarian cancer treatment studyCORRECTED-UPDATE 1-Merck KGaA-Pfizer to end late-stage ovarian cancer treatment study
feeds.reuters.com - December 21 at 3:08 PM
This page was last updated on 5/10/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.